Unit Oral Dose Compositions of Ibuprofen and Famotidine for Acute Pain and Heartburn Reduction
Summary
The USPTO published patent application US20260097023A1 for unit oral dose compositions combining ibuprofen (50-400 mg) and famotidine (3-20 mg) designed to treat acute pain while reducing the severity or risk of heartburn and upset stomach. The formulation specifies that famotidine must dissolve faster than ibuprofen within 45 minutes of administration. The application was filed on December 2, 2025, by inventor Bernard Schachtel.
What changed
The USPTO published a patent application for a pharmaceutical composition combining ibuprofen and famotidine in a single oral dose unit. The formulation specifies precise dosage ranges for both active ingredients and requires a differential dissolution rate where famotidine dissolves faster than ibuprofen within 45 minutes of administration.\n\nAffected parties in the pharmaceutical industry should monitor this application as it may indicate competitive activity in the acute pain medication space with gastrointestinal protection. Generic drug manufacturers and formulation developers should review the claims to assess potential freedom-to-operate implications for similar combination products.
What to do next
- Monitor for patent grant or office action
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
UNIT ORAL DOSE COMPOSITIONS COMPOSED OF IBUPROFEN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND FAMOTIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR THE TREATMENT OF ACUTE PAIN AND THE REDUCTION OF THE SEVERITY AND/OR RISK OF HEARTBURN AND/OR UPSET STOMACH
Application US20260097023A1 Kind: A1 Apr 09, 2026
Inventors
Bernard SCHACHTEL
Abstract
Described herein are unit oral dose compositions that reduce the severity of heartburn and/or upset stomach or the risk of the occurrence of heartburn and/or upset stomach in a human in need of taking ibuprofen or the pharmaceutically acceptable salt thereof for the treatment of acute pain wherein the human is not experiencing heartburn and/or upset stomach prior to the oral administration of the unit oral dose composition comprising orally administering to the human of a unit oral dose composition comprising (i) ibuprofen or the pharmaceutically acceptable salt thereof, wherein the amount of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen is a dosage from about 50 mg to about 400 mg per unit oral dose composition and (ii) famotidine or the pharmaceutically acceptable salt thereof, wherein famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine is at a dosage from about 3 mg to about 20 mg per unit oral dose composition, wherein the dissolution rate of famotidine or the conjugate acid of famotidine of the pharmaceutically acceptable salt of famotidine in the unit oral dose composition in said human at a specified time within 45 minutes of administration of said unit oral dose composition to said human is greater than the dissolution rate of ibuprofen or the conjugate base of ibuprofen of the pharmaceutically acceptable salt of ibuprofen in the unit oral dose composition in said human at the same specified time.
CPC Classifications
A61K 31/426 A61K 9/0053 A61K 9/2077 A61K 9/2086 A61K 31/138 A61K 31/167 A61K 31/192 A61K 31/194
Filing Date
2025-12-02
Application No.
19405788
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.